肝癌患者血清AHSG,NF-κB表达水平与肝动脉化疗栓塞术预后的相关性研究  

Correlation between Serum AHSG, NF-κB Expression Levels and Prognosis of Hepatic Artery Chemoembolization in Patients with Hepatocellular Carcinoma

作　　者：王俊霞[1] 贾如江[2] 霍浩然[2] 郭书华 WANG Jun-xia;JIA Ru-jiang;HUO Hao-ran;GUO Shu-hua(Department of Interventional,Handan Central Hospital,Hebei Handan 056000,China;Department of General Surgery,Handan Central Hospital,Hebei Handan 056000,China)

机构地区：[1]邯郸市中心医院介入科,河北邯郸056000 [2]邯郸市中心医院普外科,河北邯郸056000

出　　处：《现代检验医学杂志》2022年第2期126-131,共6页Journal of Modern Laboratory Medicine

基　　金：河北省医学科学研究课题计划项目(编号20191824)。

摘　　要：目的分析肝癌患者血清胎球蛋白A(fetuin A,AHSG)、核因子-κB(nuclear factor-κB,NF-κB)水平与经导管动脉化疗栓塞(transcatheter arterial chemoembolization,TACE)术后预后的关系。方法选取2014年5月~2016年4月在邯郸市中心医院普外科就诊并行TACE的85例肝癌患者为肝癌组,同期选取85例医院体检结果正常者为对照组。酶联免疫吸附试验法(enzyme linked immunosorbent assay,ELISA)检测肝癌组患者行TACE治疗前与对照组体检当日血清AHSG和NF-κB水平;对肝癌患者TACE术后进行为期5年的随访,记录患者生存情况;分析肝癌患者血清AHSG和NF-κB水平的相关性以及二者与临床病理特征的关系;Kaplan-Meier法分析肝癌患者血清AHSG和NF-κB水平与TACE术后预后的关系;COX回归分析影响肝癌患者TACE术后预后不良的危险因素。结果与对照组比较,肝癌组患者血清AHSG(14.57±3.69 ng/ml vs 5.29±1.34 ng/ml)和NF-κB(5.42±1.46 ng/ml vs 1.28±0.53 ng/ml)水平显著升高,差异均有统计学意义(t=21.794,24.574,均P=0.000);肝癌患者血清AHSG与NF-κB水平呈正相关(r=0.495,P=0.000);肝癌患者血清AHSG和NF-κB水平与AST水平、Child-Pugh分级、TNM分期有关(χ^(2)=7.051~17.285,均P<0.05);AHSG高表达组患者5年累积生存率低于AHSG低表达组[17.78%(8/45)vs 40.00%(16/40)],NF-κB高表达组5年累积生存率低于NF-κB低表达组[19.15%(9/47)vs 39.47%(15/38)],差异均有统计学意义(χ^(2)=5.161,P=0.023;χ^(2)=4.284,P=0.038);TNM分期高及血清AHSG和NF-κB高表达是影响肝癌患者TACE术后预后不良的危险因素(P=0.002,0.001,0.000)。结论肝癌患者血清AHSG和NF-κB水平均呈高表达,二者与肝癌患者TACE术后预后密切相关,可作为预测TACE术后预后的潜在生物标志物。Objective To analyze the relationship between serum fetuin A(AHSG), nuclear factor-κB(NF-κB) level and prognosis after transcatheter arterial chemoembolization(TACE) in patients with liver cancer. Methods From May 2014 to April 2016, 85 cases of liver cancer patients with TACE in the Department of General Surgery of Handan Central Hospital were selected as the liver cancer group, and 85 cases of normal physical examination results in the hospital were selected as the control group. Enzyme linked immunosorbent assay(ELISA) was used to detect the level of serum AHSG, NF-κB in patients with liver cancer before TACE treatment and on the day of physical examination in the control group. The patients with liver cancer were followed up for 5 years after TACE, record the patient’s survival, and analyzed the correlation between serum AHSG and NF-κB levels in patients with liver cancer and the relationship between them and clinicopathological features.The relationship between serum AHSG, NF-κB levels and prognosis of liver cancer patients after TACE was analyzed by Kaplan-Meier method.COX regression analysis was used to analyze the risk factors affecting the poor prognosis of patients with liver cancer after TACE.Results Compared with the control group, the level of serum AHSG(14.57±3.69 ng/ml vs 5.29±1.34 ng/ml), NF-κB(5.42±1.46 ng/ml vs 1.28±0.53 ng/ml)in liver cancer group was significantly higher,the differences were statistically significant(t=21.794, 24.574, all P=0.000).There was a positive correlation between the levels of serum AHSG and NF-κB in patients with liver cancer(r=0.495, P=0.000). The level of serum AHSG and NF-κB in patients with liver cancer was related to AST level, Child-Pugh grade and TNM stage(χ^(2)=7.051~17.285, all P<0.05). The 5-year cumulative survival rate of patients with AHSG high expression group was lower than that of patients with AHSG low expression group [17.78%(8/45)vs 40.00%(16/40)], the 5-year cumulative survival rate of patients with NF-κB high expression group was l

关 键 词：肝癌 胎球蛋白A 核因子-ΚB 经导管动脉化疗栓塞 

分 类 号：R735.7[医药卫生—肿瘤] R730.43[医药卫生—临床医学]